Best-Of Rankings
Every ranking on this site is computed from one dataset on a stated criterion. None is assigned.
23 rankings, each sorting the same dataset on a different question: cheapest at a maintenance dose, lowest first-year total, flat pricing, no membership, best for a given care model or commitment length.
There is no single best programme, which is why there is no single ranking. What is best depends on the dose you will hold, whether you can commit to a term, and whether you need an FDA-approved product.
Of the 32 programmes on this site, 11 have a price we read at the provider or manufacturer, 6 carry a third-party figure we have not confirmed, and 15 publish no price we can interpret. Every table shows which is which, because a comparison that mixes them without saying so is not a comparison.
First-year all-in cost
Every page in this section
Best Tirzepatide Telehealth Providers
The overall ranking, computed from all-in cost at a maintenance dose and what each programme discloses.
Best Compounded Tirzepatide Providers
Programmes dispensing compounded tirzepatide, ranked on true ongoing cost rather than entry price.
Best Zepbound Telehealth Providers
Routes to FDA-approved tirzepatide, including manufacturer self-pay.
Cheapest Tirzepatide Telehealth
Ranked by all-in monthly cost at 10 mg, membership included.
Lowest Cost Without Insurance
Cash-pay routes ranked by first-year total.
Flat-Rate Tirzepatide Providers
Programmes whose price does not rise as the dose climbs.
Providers With No Membership Fee
Programmes that charge for medication only.
Best Month-to-Month Tirzepatide Plans
No commitment, no prepayment, cancel between cycles.
Best Three-Month Tirzepatide Plans
The shortest commitment that usually carries a discount.
Best Six-Month Tirzepatide Plans
Mid-length terms and what they put at risk.
Best Twelve-Month Tirzepatide Plans
The deepest discounts and the largest non-refundable commitment.
Best Pricing at 12.5 and 15 mg
What the top of the dose ladder costs, where dose-scaled programmes hurt most.
Best Pricing at the 2.5 mg Starter Dose
The month everyone advertises, and the least representative of your year.
Best Pricing at a 10 mg Maintenance Dose
The dose most patients hold, and the one worth comparing on.
Best Providers for Insurance Support
Programmes that will work a prior authorisation rather than sell you cash-pay.
Best Cash-Pay Tirzepatide Programmes
No insurance, no prior authorisation, no formulary.
Best Providers With Live Video Visits
Programmes where a clinician appears on camera.
Best Asynchronous Tirzepatide Programmes
Questionnaire-based review, and when that is genuinely adequate.
Best Doctor-Led Tirzepatide Programmes
Named physicians and published medical leadership.
Best Providers With Labs Included
Programmes that order and pay for baseline bloodwork.
Best Providers With Coaching Included
Behavioural support bundled rather than sold separately.
Best Tirzepatide Telehealth in California
What is available in the largest state, and what the price looks like there.
Providers Available Nationwide
Programmes publishing availability in all fifty states.
The short version of the best-of rankings hub
Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.
Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $215 a month all-in, about $2,580 across a first year including titration.
The next step that actually moves things
Send two or three programmes the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.
Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.
One thing worth doing annually
Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and tirzepatide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.
An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.
Reading this alongside the rest of the site
Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.
If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.
What we would need to change our mind
A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.
All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.
What this site will not do
Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.
Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.
Who this site is not for
Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.
If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.
What stopping does, and why it belongs in a cost calculation
The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.
Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.
Why the same molecule sells across a fifteenfold range
The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.
That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.
What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.
The pharmacology behind the fees
Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.
A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.
What stopping does, and why it belongs in a cost calculation
The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.
Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.
Why the same molecule sells across a fifteenfold range
The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.
That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.
What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.
The pharmacology behind the fees
Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.
A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.